Charles River

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, dedicated to innovating cancer treatment through its unique Probody therapeutics. With a focus on developing potent and less toxic anti-cancer medications, CytomX aims to transform the lives of patients by providing a new generation of life-changing treatment options. The company emphasizes a mission-driven culture that values diversity, equity, and inclusion, recognizing that diverse perspectives enhance creativity and innovation. CytomX is committed to fostering an environment where individuals feel respected and connected, working collaboratively to achieve both corporate and individual objectives in the fight against cancer. Generated from the website

Calico, based in South San Francisco, CA, is a pioneering research and technology company dedicated to unraveling the mysteries of aging and developing interventions to enable longer and healthier lives. With a focus on understanding the biology that controls aging, Calico combines the best aspects of biotechnology and academia to tackle challenging questions about aging and age-related diseases. Founded by Arthur D. Levinson, Ph.D., Calico fosters a culture of curiosity, collaboration, and innovation, leveraging cutting-edge technology and advanced computing capabilities to drive progress in aging research. Through high-quality publications, strategic partnerships, and a growing pipeline of compounds targeting age-related diseases, Calico is at the forefront of the quest to unlock the secrets of longevity and vitality.Generated from the website

Cairn Biosciences is a San Francisco-based biotech company that specializes in discovering new medicines by mapping multiscale cell dynamics. Their proprietary COMPASS discovery platform utilizes innovative simulations of living biology to navigate complex disease biology and unlock exclusive routes to novel targets and drugs, with a focus on overcoming acquired resistance to targeted cancer therapies. With a diverse and multidisciplinary team of experts in drug discovery, disease biology, engineering, and computation, Cairn Biosciences is pioneering a new drug discovery paradigm. Their team, led by established biopharma leader and serial drug discovery innovator Mary Ludlam, is dedicated to delivering better therapeutics through their expertise in synthetic cell biology, high-throughput microscopy, computational analysis, and more.Generated from the website